Table 1 Main characteristics of the eligible studies
From: Prognostic role of CD133 expression in colorectal cancer: a meta-analysis
Study | Patient's country | Year | TNM grading/UICC staging | Technique | Number of patients | Antibody used, dilution | Cutoff of CD133 positive | Site |
|---|---|---|---|---|---|---|---|---|
Coco | Italy | 2012 | I–III | IHC | 137 | Santa Cruz 100 | > 5% | Colon or Rectum |
Hongo | Japan | 2012 | I–IV | IHC | 303 | Miltenyi Biotec 100 | > 5% | Colon or Rectum |
Zhang | China | 2012 | II–III | IHC | 125 | Novus 150 | ≥Score 4 | colon |
Xi | China | 2011 | I–IV | IHC | 201 | Abcam 200 | ≥Score 5 | Colon or Rectum |
Lugli | Switzerland | 2010 | I–IV | Tissue microarray | 1235 | Cell Signaling 100 | > 5% | Colon or Rectum |
Takahashi | Japan | 2010 | I–IV | IHC | 151 | Abcam 200 | > 50% | Colon or Rectum |
Ong | Australia | 2010 | I–IV | Tissue microarray | 501 | Miltenyi Biotech 10 | > 5% | Colon or Rectum |
Li | China | 2009 | IIIB | IHC | 104 | Abcam 150 | ≥5% | Colon or Rectum |
Horst | Germany | 2009 | I–II | IHC | 110 | Cell Signaling 100 | ≥50% | Colon |
Choi | South Korea | 2009 | 0–IV | Tissue microarray | 523 | Santa Cruz 50 | -- | Colon or Rectum |
Wang | China | 2009 | 0–IV | IHC | 73 | Abcam 200 | > 10% | Rectal |
Kojima | Japan | 2008 | I–IV | IHC | 189 | Miltenyi Biotech 100 | > 10% | Colon or Rectum |